Ipamorelin vs MGF

Ipamorelin binds to the ghrelin receptor (GHSR-1a) and stimulates dose-dependent GH release with a clean hormonal profile. Unlike GHRP-6 or hexarelin, it does not significantly stimulate appetite-related pathways or cortisol secretion at standard research doses. This selectivity makes it a frequently studied peptide for protocols where hormonal side-effect profiles are a consideration.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective growth hormone secretagogue that acts as a ghrelin receptor (GHS-R1a) agonist, valued in research for its selectivity for GH release with minimal concurrent stimulation of cortisol, prolactin, or ACTH compared to earlier GH-releasing peptides such as GHRP-2 and GHRP-6. Ipamorelin stimulates pulsatile GH secretion from pituitary somatotrophs through ghrelin receptor signaling; its selective endocrine profile was characterized preclinically and distinguishes it from less selective GHRPs, making it a widely used tool compound in GH secretagogue research and the subject of exploratory clinical development for GI motility applications. The only indexed Phase II human trial of ipamorelin examined its effects on postoperative ileus in bowel resection patients, demonstrating GI motility improvements consistent with its enteric GHS-R1a activity; no published human data addresses its effects on GH secretion, body composition, or performance outcomes in the contexts for which it is commonly used as a research compound. Ipamorelin has no FDA approval for any indication; it is a research compound with well-characterized preclinical pharmacology and a single published human trial in a GI context, and claims regarding its use for muscle gain, fat loss, or anti-aging purposes are not supported by published clinical evidence. Ipamorelin is frequently studied in combination with CJC-1295 (a GHRH analogue), with the rationale that CJC-1295 extends the GHRH pulse window while ipamorelin provides selective GHS-R1a stimulation without additional cortisol or prolactin burden. The CJC-1295 ipamorelin combination is among the most commonly researched GH secretagogue pairings in both the research literature and in compounded clinical protocols, and both compounds are available through telehealth providers and compounding pharmacies in the PeptideBase directory. A triple combination of sermorelin, ipamorelin, and CJC-1295 has also been explored in research contexts as a multi-pathway approach to GH axis support, though no published human trial evidence supports this specific combination. Ipamorelin's side effect profile in preclinical and limited clinical research is considered favorable relative to earlier GHRPs. Unlike GHRP-2 and GHRP-6, which produce dose-dependent elevations in cortisol, prolactin, and ACTH, ipamorelin selectively stimulates GH release with minimal effect on these hormones at standard research doses — its selectivity was a primary design objective in its development. Commonly reported observations in research contexts include transient water retention (attributed to IGF-1-mediated sodium reabsorption at higher doses), mild injection-site discomfort, and occasionally headache or flushing shortly after administration, consistent with the acute GH pulse. Long-term use considerations include potential receptor desensitization with continuous daily dosing, which is why cycling protocols (e.g., 5 days on, 2 days off, or monthly off-cycles) are common in research designs. At doses substantially exceeding research norms, GH-class effects such as peripheral paresthesia, joint stiffness, and carpal tunnel-type symptoms have been observed — consistent with GH-excess effects across secretagogue and exogenous HGH literature. Ipamorelin's long-term safety profile in humans has not been established through controlled clinical trials; all available safety observations derive from preclinical studies and the single published Phase II GI motility trial, which was short-duration and not designed to assess endocrine safety endpoints.

Splice variant of IGF-1; acts locally at site of muscle damage to activate satellite cells (muscle stem cells) for repair and hypertrophy

Mechano growth factor (MGF), also designated IGF-1Ec, is a splice variant of the IGF-1 gene produced locally in skeletal muscle in response to mechanical loading and tissue microdamage, and is proposed to function as an autocrine/paracrine signal that activates muscle satellite cells and initiates the early repair response, a role distinct from the endocrine actions of systemic IGF-1. The unique C-terminal E-peptide domain of MGF is proposed to be the bioactive moiety responsible for satellite cell activation and progenitor cell proliferation, acting through mechanisms that are at least partially independent of IGF-1R and specific to the mechanical stress response rather than systemic growth signaling. Human muscle progenitor cell studies have demonstrated that the MGF E-peptide activates muscle progenitor cells and enhances their fusion potential across different age groups, suggesting a role in the age-related decline in muscle repair capacity. MGF is a research compound with no regulatory approval in any jurisdiction; exogenous administration is investigational, no human clinical pharmacokinetic or safety data has been established, and published evidence is limited to in vitro and preclinical contexts. MGF vs PEG-MGF: native MGF has a very short half-life in circulation, limiting its duration of action after exogenous administration. PEG-MGF (pegylated MGF) is a chemically stabilized version in which polyethylene glycol is conjugated to the peptide to extend its biological half-life — the same technology used to extend the half-life of therapeutic proteins such as PEG-EPO. Research compound suppliers often offer both forms; PEG-MGF is the more commonly studied variant in animal myopathy models for this pharmacokinetic reason. Neither form has human clinical data. MGF in muscle research: interest in MGF as a research compound centers on its proposed role in the lag phase of muscle repair following eccentric exercise-induced damage — the window when satellite cells are activated before proliferating and fusing into existing myofibers. In aged muscle, MGF expression following mechanical loading is reduced relative to young tissue, and this deficit has been proposed as a contributing factor to age-related sarcopenia in the research literature. Providers offering research peptides in the performance and recovery category are listed in the PeptideBase directory.